Cargando…

Improving nanotherapy delivery and action through image-guided systems pharmacology

Despite recent advances in the translation of therapeutic nanoparticles (TNPs) into the clinic, the field continues to face challenges in predictably and selectively delivering nanomaterials for the treatment of solid cancers. The concept of enhanced permeability and retention (EPR) has been coined...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Thomas S.C., Garlin, Michelle A., Weissleder, Ralph, Miller, Miles A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956809/
https://www.ncbi.nlm.nih.gov/pubmed/31938046
http://dx.doi.org/10.7150/thno.37215
_version_ 1783487209290072064
author Ng, Thomas S.C.
Garlin, Michelle A.
Weissleder, Ralph
Miller, Miles A.
author_facet Ng, Thomas S.C.
Garlin, Michelle A.
Weissleder, Ralph
Miller, Miles A.
author_sort Ng, Thomas S.C.
collection PubMed
description Despite recent advances in the translation of therapeutic nanoparticles (TNPs) into the clinic, the field continues to face challenges in predictably and selectively delivering nanomaterials for the treatment of solid cancers. The concept of enhanced permeability and retention (EPR) has been coined as a convenient but simplistic descriptor of high TNP accumulation in some tumors. However, in practice EPR represents a number of physiological variables rather than a single one (including dysfunctional vasculature, compromised lymphatics and recruited host cells, among other aspects of the tumor microenvironment) — each of which can be highly heterogenous within a given tumor, patient and across patients. Therefore, a clear need exists to dissect the specific biophysical factors underlying the EPR effect, to formulate better TNP designs, and to identify patients with high-EPR tumors who are likely to respond to TNP. The overall pharmacology of TNP is governed by an interconnected set of spatially defined and dynamic processes that benefit from a systems-level quantitative approach, and insights into the physiology have profited from the marriage between in vivo imaging and quantitative systems pharmacology (QSP) methodologies. In this article, we review recent developments pertinent to image-guided systems pharmacology of nanomedicines in oncology. We first discuss recent developments of quantitative imaging technologies that enable analysis of nanomaterial pharmacology at multiple spatiotemporal scales, and then examine reports that have adopted these imaging technologies to guide QSP approaches. In particular, we focus on studies that have integrated multi-scale imaging with computational modeling to derive insights about the EPR effect, as well as studies that have used modeling to guide the manipulation of the EPR effect and other aspects of the tumor microenvironment for improving TNP action. We anticipate that the synergistic combination of imaging with systems-level computational methods for effective clinical translation of TNPs will only grow in relevance as technologies increase in resolution, multiplexing capability, and in the ability to examine heterogeneous behaviors at the single-cell level.
format Online
Article
Text
id pubmed-6956809
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-69568092020-01-14 Improving nanotherapy delivery and action through image-guided systems pharmacology Ng, Thomas S.C. Garlin, Michelle A. Weissleder, Ralph Miller, Miles A. Theranostics Review Despite recent advances in the translation of therapeutic nanoparticles (TNPs) into the clinic, the field continues to face challenges in predictably and selectively delivering nanomaterials for the treatment of solid cancers. The concept of enhanced permeability and retention (EPR) has been coined as a convenient but simplistic descriptor of high TNP accumulation in some tumors. However, in practice EPR represents a number of physiological variables rather than a single one (including dysfunctional vasculature, compromised lymphatics and recruited host cells, among other aspects of the tumor microenvironment) — each of which can be highly heterogenous within a given tumor, patient and across patients. Therefore, a clear need exists to dissect the specific biophysical factors underlying the EPR effect, to formulate better TNP designs, and to identify patients with high-EPR tumors who are likely to respond to TNP. The overall pharmacology of TNP is governed by an interconnected set of spatially defined and dynamic processes that benefit from a systems-level quantitative approach, and insights into the physiology have profited from the marriage between in vivo imaging and quantitative systems pharmacology (QSP) methodologies. In this article, we review recent developments pertinent to image-guided systems pharmacology of nanomedicines in oncology. We first discuss recent developments of quantitative imaging technologies that enable analysis of nanomaterial pharmacology at multiple spatiotemporal scales, and then examine reports that have adopted these imaging technologies to guide QSP approaches. In particular, we focus on studies that have integrated multi-scale imaging with computational modeling to derive insights about the EPR effect, as well as studies that have used modeling to guide the manipulation of the EPR effect and other aspects of the tumor microenvironment for improving TNP action. We anticipate that the synergistic combination of imaging with systems-level computational methods for effective clinical translation of TNPs will only grow in relevance as technologies increase in resolution, multiplexing capability, and in the ability to examine heterogeneous behaviors at the single-cell level. Ivyspring International Publisher 2020-01-01 /pmc/articles/PMC6956809/ /pubmed/31938046 http://dx.doi.org/10.7150/thno.37215 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Ng, Thomas S.C.
Garlin, Michelle A.
Weissleder, Ralph
Miller, Miles A.
Improving nanotherapy delivery and action through image-guided systems pharmacology
title Improving nanotherapy delivery and action through image-guided systems pharmacology
title_full Improving nanotherapy delivery and action through image-guided systems pharmacology
title_fullStr Improving nanotherapy delivery and action through image-guided systems pharmacology
title_full_unstemmed Improving nanotherapy delivery and action through image-guided systems pharmacology
title_short Improving nanotherapy delivery and action through image-guided systems pharmacology
title_sort improving nanotherapy delivery and action through image-guided systems pharmacology
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6956809/
https://www.ncbi.nlm.nih.gov/pubmed/31938046
http://dx.doi.org/10.7150/thno.37215
work_keys_str_mv AT ngthomassc improvingnanotherapydeliveryandactionthroughimageguidedsystemspharmacology
AT garlinmichellea improvingnanotherapydeliveryandactionthroughimageguidedsystemspharmacology
AT weisslederralph improvingnanotherapydeliveryandactionthroughimageguidedsystemspharmacology
AT millermilesa improvingnanotherapydeliveryandactionthroughimageguidedsystemspharmacology